Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712042 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL292707 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL592816 | 0.88 | ALDH1A1 (0.41) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL2223898 | 0.88 | ALDH1A1 (0.41) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL2245757 | 0.88 | ALDH1A1 (0.41) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL591257 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TSHRMAPK1SMN1; SMN2DUT | |
| SCHEMBL336309 | 0.85 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPK1SMN1; SMN2DUT | |
| SCHEMBL335223 | 0.85 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPK1SMN1; SMN2DUT | |
| SCHEMBL632976 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRMAPK1MEN1KMT2A | |
| SCHEMBL111369 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TSHRMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3549930-B1 | NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED | UNIV HIROSHIMA (JP) | 2023-07-19 | — | — | EP | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| US-11203565-B2 | Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | HIROSHIMA UNIVERSITY (JP) | 2021-12-21 | — | — | US | disclosed |
| WO-2021190727-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3549930-A1 | NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED | Hiroshima University (JP) | 2019-10-09 | — | — | EP | disclosed |
| WO-2010041218-A2 | OXAZOLIDINYL ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| WO-2010015985-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009104147-A2 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009104159-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| WO-2009080761-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080769-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| EP-2032551-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | ALDH1A1 1692/4885TSHR 4338/4885MAPK1 2684/4885 |
| US-11203565-B2 | Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | PIN1, APC, GSKIP | ALDH1A1 3207/4885TSHR 4666/4885MAPK1 162/4885 |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | ALDH1A1 1692/4885TSHR 4338/4885MAPK1 2684/4885 |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | ALDH1A1 568/4885TSHR 3964/4885MAPK1 1267/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | ALDH1A1 842/4885TSHR 1921/4885MAPK1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.